Skip to main content
. 2017 Nov 2;38(1):19–27. doi: 10.1007/s40261-017-0580-6

Fig. 3.

Fig. 3

 Changes in body weight as a result of add-on SGLT2 inhibitor treatment in patients with pretreatment HbA1c levels < 7.7% and those with pretreatment HbA1c levels ≥ 7.7%. Data are mean ± standard deviation. SGLT2 sodium-glucose co-transporter 2, HbA1c glycated hemoglobin